Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx ...

AstraZeneca was among the first multinational pharmaceutical firms to invest deeply in China's healthcare sector. Through ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Live Updates Live Coverage Updates appear automatically as they are published. Get The Best Tempus AI Live Earnings Coverage ...

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss ...

Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving ...